Erythrocyte-active agents and treatment of sickle cell disease
C Brugnara, L De Franceschi, Y Beuzard - Seminars in hematology, 2001 - Elsevier
The sickle hemoglobin (HbS)-containing erythrocyte and its membrane represent a logical
target for sickle cell disease therapy. Several antisickling agents which interfere with HbS
polymerization have been studied over the last 30 years, but none has overcome the
challenge of delivering high concentrations inside the sickle red blood cell without toxicity.
The sickle erythrocyte membrane has also been targeted for therapeutic developments.
Prevention of sickle cell dehydration by use of specific blockers of ion transport pathways …
target for sickle cell disease therapy. Several antisickling agents which interfere with HbS
polymerization have been studied over the last 30 years, but none has overcome the
challenge of delivering high concentrations inside the sickle red blood cell without toxicity.
The sickle erythrocyte membrane has also been targeted for therapeutic developments.
Prevention of sickle cell dehydration by use of specific blockers of ion transport pathways …